- Home
- LEE vs BOLD Comparison
LEE vs BOLD Comparison
Compare LEE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LEE | BOLD |
|---|---|---|
| Founded | 1890 | 2018 |
| Country | United States | United States |
| Employees | N/A | 64 |
| Industry | Newspapers/Magazines | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 26.9M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | LEE | BOLD |
|---|---|---|
| Price | $4.65 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 58.9K | ★ 135.2K |
| Earning Date | 02-05-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $562,341,000.00 | N/A |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $1.00 |
| 52 Week High | $15.15 | $3.12 |
Technical Indicators
Market Signals| Indicator | LEE | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 64.26 | 47.83 |
| Support Level | $3.58 | $1.17 |
| Resistance Level | $4.51 | $1.37 |
| Average True Range (ATR) | 0.44 | 0.08 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 59.24 | 24.00 |
Price Performance
Historical ComparisonAbout LEE Lee Enterprises Incorporated
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.